eFFECTOR Therapeutics Inc (FRA:LWK)
€ 1.245 0.025 (2.05%) Market Cap: 5.48 Mil Enterprise Value: 694,000.00 PE Ratio: 0 PB Ratio: 5.90 GF Score: 23/100

eFFECTOR Therapeutics Inc at JMP Securities Life Sciences Conference Transcript

May 15, 2023 / 01:30PM GMT
Release Date Price: €14.38 (+16.40%)
Unidentified Analyst

Excellent. So good morning, everyone. Welcome to the JMP Securities healthcare conference. It's my pleasure to welcome all of you and to welcome our first presenting company, eFFECTOR Therapeutics. Presenting for the company is Steve Worland, President and CEO.

And just so you guys know, eFFECTOR is a developer of Selective Translation Regulator Inhibitors, which is a mouthful, but it is a new class of, I want to say, compounds and development that not too many people are doing. So here to tell us about the story is Steve.

Steve Worland
eFFECTOR Therapeutics, Inc. - President & CEO

Great. Thank you very much, [Ryan]. And thank you for the opportunity to present today.

So we really view eFFECTOR Therapeutics as developing a next generation of targeted therapeutics. We're going after pathways that are well recognized, but a different point of intervention and a different outcome to block tumor cell growth and ultimately to reduce tumor burden in patients.

So everybody's familiar with the RAS and the PI3K pathways.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot